文献速递胸部肿瘤

新辅助化疗联合纳武利尤单抗治疗可切除非小细胞肺癌的II期NADIM试验

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2020-09-24

NADIM是一项在西班牙18家医院开展的单臂II期试验,纳入46例可切除IIIA期NSCLC患者,术前接受3周期紫杉醇+卡铂+纳武利尤单抗,术后纳武利尤单抗辅助治疗1年。

要点

  • ≥3级治疗相关不良事件发生率30%,最常见为脂肪酶升高和发热性中性粒细胞减少。
  • 不良事件未导致手术延迟或死亡,支持该方案在可切除IIIA期患者中应用。

核心结论

  • 新辅助化疗联合纳武利尤单抗在可切除IIIA期NSCLC中显示出支持性结果,可能改变局部晚期肺癌被视为潜在致死性疾病的认知。

研究设计与样本

  • 开放标签、多中心、单臂II期试验,在西班牙18家医院开展,纳入46例可切除IIIA期NSCLC患者。
  • 患者接受3周期新辅助紫杉醇(200 mg/m2)+卡铂(AUC 6)+纳武利尤单抗(360 mg)每21天,术后纳武利尤单抗辅助治疗1年。
  • 主要终点为24个月无进展生存率,在改良意向治疗人群和符合方案人群中评估。

主要发现

  • 46例中43例(93%)在新辅助治疗期间发生治疗相关不良事件,14例(30%)发生≥3级治疗相关不良事件。
  • 最常见≥3级治疗相关不良事件为脂肪酶升高(3例[7%])和发热性中性粒细胞减少(3例[7%])。

临床怎么用

  • 结果支持在可切除IIIA期NSCLC患者中,于铂类化疗基础上加用新辅助纳武利尤单抗。

局限性

  • 本研究为单臂II期试验,样本量有限,需进一步随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC. METHODS: This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. Eligible patients were aged 18 years or older with histologically or cytologically documented treatment-naive American Joint Committee on Cancer-defined stage IIIA NSCLC that was deemed locally to be surgically resectable by a multidisciplinary clinical team, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and carboplatin (area under curve 6; 6 mg/mL per min) plus nivolumab (360 mg) on day 1 of each 21-day cycle, for three cycles before surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg every 2 weeks for 4 months, followed by 480 mg every 4 weeks for 8 months). The primary endpoint was progression-free survival at 24 months, assessed in the modified intention-to-treat population, which included all patients who received neoadjuvant treatment, and in the per-protocol population, which included all patients who had tumour resection and received at least one cycle of adjuvant treatment. Safety was assessed in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03081689, and is ongoing but no longer recruiting patients. FINDINGS: Between April 26, 2017, and Aug 25, 2018, we screened 51 patients for eligibility, of whom 46 patients were enrolled and received neoadjuvant treatment. At the time of data cutoff (Jan 31, 2020), the median duration of follow-up was 24·0 months (IQR 21·4-28·1) and 35 of 41 patients who had tumour resection were progression free. At 24 months, progression-free survival was 77·1% (95% CI 59·9-87·7). 43 (93%) of 46 patients had treatment-related adverse events during neoadjuvant treatment, and 14 (30%) had treatment-related adverse events of grade 3 or worse; however, none of the adverse events were associated with surgery delays or deaths. The most common grade 3 or worse treatment-related adverse events were increased lipase (three [7%]) and febrile neutropenia (three [7%]). INTERPRETATION: Our results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC. Neoadjuvant chemoimmunotherapy could change the perception of locally advanced lung cancer as a potentially lethal disease to one that is curable. FUNDING: Bristol-Myers Squibb, Instituto de Salud Carlos III, European Union's Horizon 2020 research and innovation programme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020. PMID: 32979984. doi:10.1016/S1470-2045(20)30453-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。